文献速递鼻科

嗜酸性慢性鼻窦炎术后需全身用药的预测因素

Systemic medication requirement in post-surgical patients with eosinophilic chronic rhinosinusitis.
PubMed 文献 · Rhinology · 2021-01-01

研究纳入222例接受内镜鼻窦手术并建立新鼻窦腔的成人嗜酸性慢性鼻窦炎患者,随访至少12个月。结果显示5.4%需长期全身治疗,术前血嗜酸性粒细胞>0.455×10^9/L者需全身用药的风险高9.27倍,哮喘、特应质和阿司匹林敏感亦为预测因素。

要点

  • 术后仅5.4%的eCRS患者需长期全身治疗。
  • 术前血嗜酸性粒细胞>0.455×10^9/L预测局部治疗失败。
  • 哮喘、特应质、阿司匹林敏感也预测需全身治疗。

核心结论

  • 术前血嗜酸性粒细胞计数>0.45×10^9/L与eCRS现代管理下局部治疗失败相关。
  • 血清嗜酸性粒细胞增多可能预测疾病进展及需全身治疗(如生物制剂)的患者。

研究设计与样本

  • 连续纳入成人(>18岁)eCRS患者,均接受内镜鼻窦手术并建立新鼻窦腔,随访至少12个月。
  • 共评估222例患者,随访2.76年。

主要发现

  • 5.4%的患者需要长期全身治疗。
  • 受试者工作特征曲线分析预测局部治疗失败的嗜酸性粒细胞计数截断值为0.455×10^9/L。
  • 哮喘、特应质和阿司匹林敏感也预测需长期全身治疗。
  • 鼻息肉和修正手术与需长期全身治疗无关联。
  • 多因素logistic回归显示血嗜酸性粒细胞>0.455×10^9/L者需全身用药的可能性高9.27倍。

临床怎么用

  • 术前可检测血嗜酸性粒细胞计数,>0.455×10^9/L者提示局部治疗失败风险高。
  • 对合并哮喘、特应质或阿司匹林敏感者应关注需全身治疗的可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Eosinophilic chronic rhinosinusitis (eCRS) is contemporarily managed by surgical creation of a 'neo-sinus' cavity and corticosteroid irrigations. While most patients gain control of their disease with this approach, similar to preventive inhaler therapy in asthma, some patients need systemic therapies. This study aimed to define those patients needing ongoing systemic therapy for eCRS. METHODS: Consecutive adult patients (>18 years) who were seen at a tertiary referral clinic, diagnosed as eCRS and underwent endoscopic sinus surgery were included. Patients were followed up for a minimum of 12 months. All patients had a simple neo- sinus cavity surgically created and used initially a once daily topical corticosteroid irrigation maintenance therapy. Patients who re- quired long term systemic oral corticosteroids and/or biologic therapy were compared to those who remained on topical control. RESULTS: 222 patients with eCRS were assessed (follow-up 2.76 years). Long term systemic therapy was required in 5.4% of pa- tients. Receiver operating curve analysis predicted local treatment failure at an eosinophil count cut-off level 0.455x109/L. Asthma, atopy and aspirin sensitivity also predicted long term systemic therapy. There were no associations with nasal polyposis or revi- sion surgery. Multivariate logistic regression showed elevated blood eosinophil count >0.455 x109/L was 9.27 times more likely to require for systemic medication. CONCLUSION: Pre-operative blood eosinophil count >0.45 x109/L was associated with failure of local therapy following contem- porary management of eCRS. The quantitative value of serum eosinophilia may be a useful predictor of disease progression and those patients in need of systemic therapies, such as biologic agents.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Ho J, Li W, Grayson JW, et al. Systemic medication requirement in post-surgical patients with eosinophilic chronic rhinosinusitis. Rhinology. 2021. PMID: 32720937. doi:10.4193/Rhin20.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。